美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

IC Power Ltd.

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：2.84億

流通股本：2,590.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):1.38

每股收益(LYR):1.25

淨資產收益率：--

總資產收益率：--

市淨率：0.00

市盈率(LYR):- -

資料載入中...

總覽公司新聞公告

港股異動 | 諾誠健華-B(09969)漲6% Tafasitamab納入多省市18項地方商保即將發布ICP-192治療膽管癌最新研究數據

Mirum製藥公司(MIRM)將停止對volixibat在ICP中的OHANA研究

凤凰网港股

帝人在進博：拳頭產品齊亮相環保理念入人心

諾誠健華第二代泛TRK抑制劑ICP-723完成首例青少年患者給藥

直擊業績會 | 萊伯泰科(688056.SH)：今年在研的ICP-MS/MS進展順利暫定目標是年底可為客户提供產品

諾誠健華自主研發的BCL2抑制劑ICP-248獲批臨床

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ICP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ICP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICP\",,,,,undefined,":{"symbol":"ICP","market":"US","secType":"STK","nameCN":"IC Power Ltd.","latestPrice":0,"timestamp":1781726400000,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":25900000,"shares":284358010,"eps":1.382111,"marketStatus":"已收盤","change":0,"latestTime":"06-17 16:00:00 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.382111,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1781769600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICP\",,,,,undefined,":{"symbol":"ICP","floatShares":25900000,"roa":"--","roe":"--","lyrEps":1.24644,"shares":284358010,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"0.00","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":1.382111,"divideRate":0,"volume":0,"delay":0,"ttmEps":1.382111,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ICP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ICP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ICP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ICP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2302834014","title":"港股異動 | 諾誠健華-B(09969)漲6% Tafasitamab納入多省市18項地方商保 即將發布ICP-192治療膽管癌最新研究數據","url":"https://stock-news.laohu8.com/highlight/detail?id=2302834014","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2302834014?lang=zh_tw&edition=fundamental","pubTime":"2023-01-12 10:11","pubTimestamp":1673489485,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华-B盘初走高，升约6%。公司即将公布FGFR抑制剂Gunagratinib治疗胆管癌的最新研究数据。截至发稿，诺诚健华5.96%，报14.58港元，成交额0.10亿港元。日前，诺诚健华宣布，目前，新型CD19单抗创新药Tafasitamab已纳入多个省市的18项地方商保的海外特药目录。中信证券最新评论称，公司奥布替尼其他适应症正常进行，多里程碑事件有望近一年陆续落地。维持“买入”评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/860785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","688428","BK0239","BK1574","BK1161","ICP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2287509142","title":"Mirum製藥公司(MIRM)將停止對volixibat在ICP中的OHANA研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2287509142","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2287509142?lang=zh_tw&edition=fundamental","pubTime":"2022-11-29 23:34","pubTimestamp":1669736053,"startTime":"0","endTime":"0","summary":"Mirum制药公司宣布停止volixibat治疗妊娠肝内胆汁淤积症的OHANA研究，原因是纳入的可行性。ICP是妊娠期间胆汁淤积的一种情况，伴有瘙痒和胆汁酸水平升高，可导致胎儿并发症。然而，由于在这种高风险怀孕的情况下注册面临挑战，Mirum决定停止OHANA，这使得公司可以优先考虑其他项目。Mirum正在继续推进LIVMARLI和volixibat有可能改变患者生活的适应症的广泛管道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=2723697fb9f2765e2380fe7cb78a3c3f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRM","BK1574","BK1191","ICP","01477","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2283788255","title":"帝人在進博： 拳頭產品齊亮相 環保理念入人心","url":"https://stock-news.laohu8.com/highlight/detail?id=2283788255","media":"视频","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2283788255?lang=zh_tw&edition=fundamental","pubTime":"2022-11-15 10:33","pubTimestamp":1668479589,"startTime":"0","endTime":"0","summary":"11 月 10 日， 第五届中国国际进口博览会 在上海圆满落幕。进 博会走过五年， 其国际采购、投资促进、人文交流、开放合作四大平台作用愈发明显 。第 五届进博会共有来自 127 个国家和地区的 2800 多家企业参加企业商业展，按一年计意向 成交金额为 73...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.zol.com.cn/807/8071102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zol_stock","symbols":["ICP","FRP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2279765208","title":"諾誠健華第二代泛TRK抑制劑ICP-723完成首例青少年患者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2279765208","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2279765208?lang=zh_tw&edition=fundamental","pubTime":"2022-10-31 11:23","pubTimestamp":1667186580,"startTime":"0","endTime":"0","summary":"北京2022年10月31日 /美通社/ -- 生物医药高科技公司诺诚健华今天宣布，公司自主研发的第二代泛TRK小分子抑制剂ICP-723在中山大学肿瘤防治中心儿童肿瘤科完成首例青少年患者给药，这也是ICP-723在成人患者中显示良好安全性和有效性后，首次在青少年患者中开展临床研究。诺诚健华也已经在美国进行ICP-723的临床研究，目前在第一个剂量组尚未观察到剂量限制性毒性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3919319_ZH19319_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["09969","BK1161","TRK","BK0239","ICP","BK1574","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2267850149","title":"直擊業績會 | 萊伯泰科(688056.SH)：今年在研的ICP-MS/MS進展順利 暫定目標是年底可為客户提供產品","url":"https://stock-news.laohu8.com/highlight/detail?id=2267850149","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2267850149?lang=zh_tw&edition=fundamental","pubTime":"2022-09-15 16:54","pubTimestamp":1663232045,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月15日，莱伯泰科在业绩说明会上表示，质谱业务属于公司的新业务板块，今年在研的ICP-MS/MS进展顺利，目前样机已搭建，暂定目标是年底可以为客户提供产品。截至目前，公司ICP-MS产品已在半导体、医疗、环保等传统领域实现了产品销售，并获得了半导体行业芯片生产头部企业的复购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/792466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4504","ICP","BK4127","688056","MS","BK4534","BK0225","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2267830849","title":"諾誠健華自主研發的BCL2抑制劑ICP-248獲批臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2267830849","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2267830849?lang=zh_tw&edition=fundamental","pubTime":"2022-09-13 08:30","pubTimestamp":1663029000,"startTime":"0","endTime":"0","summary":"北京2022年9月13日 /美通社/ -- 生物医药高科技公司诺诚健华今日宣布，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的BCL2抑制剂ICP-248已获批开展临床试验，成为公司在血液瘤领域第五款进入临床的创新药，也是公司第13款进入临床的创新药。诺诚健华联合创始人、董事长兼首席执行官崔霁松博士说：\"ICP-248将进一步加强我们在血液瘤领域的管线实力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/3869471_ZH69471_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ICP","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}]}}